HUP0303108A2 - Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0303108A2 HUP0303108A2 HU0303108A HUP0303108A HUP0303108A2 HU P0303108 A2 HUP0303108 A2 HU P0303108A2 HU 0303108 A HU0303108 A HU 0303108A HU P0303108 A HUP0303108 A HU P0303108A HU P0303108 A2 HUP0303108 A2 HU P0303108A2
- Authority
- HU
- Hungary
- Prior art keywords
- optionally substituted
- group
- independently
- hydrogen atom
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108090000613 Cathepsin S Proteins 0.000 abstract 1
- 102100035654 Cathepsin S Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
A találmány tárgya az (I) általános képletű vegyületek vagygyógyászatilag elfogadható sói, amidjai vagy észterei, illetvesztereoizomer formái, ahol a képletben Ar2 jelentése adott esetbenszubsztituált monociklusos vagy biciklusos gyűrűrendszer, ami adottesetben kondenzált, és adott esetben 1-5 heteroatomot tartalmazgyűrűtagonként, amelyek egymástól függetlenül O, S, N, SO2 és C=Olehetnek; R5 és R6 jelentése egymástól függetlenül hidrogénatom vagyalkilcsoport; R7 és R8 jelentése egymástól függetlenül hidrogénatom,alkil-, alkenil-, alkoxi-, alkiltiocsoport, halogénatom vagy 4-7 tagúkarbociklusos vagy heterociklusos csoport; vagy R7 és R8 jelentéseegyütt egy adott esetben szubsztituált 5-7 tagú karbociklusos vagyheterociklusos gyűrű; n értéke 0, 1 vagy 2; G jelentése adott esetbenszubsztituált alkéndiil- vagy alkándiilcsoport; Ar jelentése adottesetben szubsztituált monociklusos- vagy biciklusos aril- vagyheteroaril gyűrű; W jelentése O, S, NR27, C=O, (C=O)NH, NH(C=O), CHR28vagy egy kovalens kötés, RZ jelentése hidrogénatom vagyhidroxilcsoport és a szaggatott vonal nincs jelen; vagy RZ nincs jelenés a szaggatott vonal egy sp2 kötést jelent; R27 jelentése többekközött hidrogénatom, alkil-, alkenil-, fenil-, naftil-, benzil-,fenetil-, heterociklusos csoport, acil-, aroilcsoport, vagy R27 és azAr2 egy része együttesen egy adott esetben szubsztituált 5 vagy 6 tagúheterociklusos gyűrűt alkothat. A találmány tárgya továbbá fentivegyületeket tartalmazó gyógyászati készítmény. A találmány szerintivegyületek a cathepsin S-sel mediált állapotok, így például azautoimmun-betegség kezelésére alkalmasak. Ó
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22517800P | 2000-08-14 | 2000-08-14 | |
| US60/225,178 | 2000-08-14 | ||
| PCT/US2001/025290 WO2002014315A2 (en) | 2000-08-14 | 2001-08-10 | Substituted pyrazoles |
| US09/927,324 | 2001-08-10 | ||
| US09/927,324 US6953793B2 (en) | 2000-08-14 | 2001-08-10 | Substituted pyrazoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0303108A2 true HUP0303108A2 (hu) | 2004-01-28 |
| HUP0303108A3 HUP0303108A3 (en) | 2012-10-29 |
| HU230538B1 HU230538B1 (hu) | 2016-11-28 |
Family
ID=26919364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303108A HU230538B1 (hu) | 2000-08-14 | 2001-08-10 | Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6953793B2 (hu) |
| EP (1) | EP1309593B1 (hu) |
| JP (1) | JP5049447B2 (hu) |
| KR (1) | KR100837193B1 (hu) |
| AT (1) | ATE320427T1 (hu) |
| AU (2) | AU8645401A (hu) |
| BR (1) | BRPI0113286B8 (hu) |
| CA (1) | CA2419552C (hu) |
| CZ (1) | CZ307185B6 (hu) |
| DE (1) | DE60118004T2 (hu) |
| DK (1) | DK1309593T3 (hu) |
| ES (1) | ES2261463T3 (hu) |
| HK (1) | HK1055422A1 (hu) |
| HU (1) | HU230538B1 (hu) |
| MX (1) | MXPA03001422A (hu) |
| NZ (1) | NZ524191A (hu) |
| PL (1) | PL213103B1 (hu) |
| PT (1) | PT1309593E (hu) |
| RU (1) | RU2317988C2 (hu) |
| WO (1) | WO2002014315A2 (hu) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| PT1309591E (pt) * | 2000-08-14 | 2007-04-30 | Ortho Mcneil Pharm Inc | Pirazoles substituídos |
| MXPA03001422A (es) * | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles substituidos. |
| US20050101587A9 (en) * | 2000-08-14 | 2005-05-12 | Butler Christopher R. | Method for treating allergies using substituted pyrazoles |
| WO2002051983A2 (en) * | 2000-12-22 | 2002-07-04 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
| MXPA03009602A (es) * | 2001-04-18 | 2004-04-02 | Euro Celtique Sa | Analogos de nociceptina. |
| EP1598340B1 (en) * | 2001-04-18 | 2009-03-04 | Euro-Celtique S.A. | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain |
| US20040147503A1 (en) * | 2002-06-04 | 2004-07-29 | Sheila Zipfeil | Novel compounds and compositions as cathepsin inhibitors |
| JP4509028B2 (ja) | 2002-09-24 | 2010-07-21 | ノバルティス アーゲー | 有機化合物 |
| US7384970B2 (en) | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
| US7109243B2 (en) | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
| US7173051B2 (en) | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
| US7256207B2 (en) | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
| FR2885904B1 (fr) * | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| UA95777C2 (en) * | 2005-06-22 | 2011-09-12 | Кемосентрикс, Инк. | Azaindazole compounds and methods of use |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| CL2007003590A1 (es) * | 2006-12-12 | 2008-02-29 | Wyeth Corp | Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt |
| US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| MX2010014223A (es) | 2008-06-20 | 2011-01-21 | Novartis Ag | Composiciones pediatricas para el tratamiento de esclerosis multiple. |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| EA201170349A1 (ru) * | 2008-08-18 | 2011-08-30 | Йейл Юниверсити | Модуляторы mif |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| US20120142928A1 (en) | 2009-08-12 | 2012-06-07 | Janssen Pharmaceutica Nv | Process for the preparation of cathepsin s inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| LT3176170T (lt) | 2012-06-13 | 2019-04-25 | Incyte Holdings Corporation | Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9458137B2 (en) | 2012-11-05 | 2016-10-04 | Nantbioscience, Inc. | Substituted indol-5-ol derivatives and their therapeutical applications |
| WO2014078257A1 (en) | 2012-11-14 | 2014-05-22 | Glaxosmithkline Llc | Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2968332A4 (en) | 2013-03-15 | 2016-08-03 | Nantbioscience Inc | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
| MX393494B (es) | 2013-04-19 | 2025-03-24 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107001332B (zh) * | 2014-12-02 | 2020-05-15 | 豪夫迈·罗氏有限公司 | 哌啶衍生物 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA51229A (fr) | 2015-02-20 | 2021-03-24 | Incyte Corp | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| US10793567B2 (en) | 2017-01-11 | 2020-10-06 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20200037286A (ko) | 2017-08-07 | 2020-04-08 | 로딘 테라퓨틱스, 인크. | 히스톤 데아세틸라제의 비사이클릭 억제제 |
| EP3694322B1 (en) | 2017-10-09 | 2024-07-03 | Terumo BCT Biotechnologies, LLC | Lyophilization container and method of using same |
| TWI870349B (zh) | 2018-05-04 | 2025-01-21 | 美商英塞特公司 | Fgfr抑制劑之固體形式及其製備方法 |
| EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| JP7471316B2 (ja) | 2019-03-14 | 2024-04-19 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | マルチパート凍結乾燥容器 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN115835908A (zh) | 2019-10-14 | 2023-03-21 | 因赛特公司 | 作为fgfr抑制剂的双环杂环 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP2023505257A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US856514A (en) * | 1907-03-15 | 1907-06-11 | William T Adams | Cheese-cutter. |
| US3743409A (en) | 1971-06-11 | 1973-07-03 | Xerox Corp | Cutter assembly |
| JPS5090172A (hu) | 1973-12-13 | 1975-07-19 | ||
| US3994890A (en) | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
| JPS5640714B2 (hu) * | 1974-03-04 | 1981-09-22 | ||
| DK27383A (da) | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| FR2642759B1 (fr) | 1989-02-09 | 1991-05-17 | Laboratorios Esteve Sa | Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante |
| FR2673628B1 (fr) | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
| US5264576A (en) | 1992-10-22 | 1993-11-23 | Hoechst-Roussel Pharmaceuticals Incorporated | Pyrazolo[4,3-c]pyridines which are intermediates |
| FR2705962B1 (fr) * | 1993-06-03 | 1995-07-13 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
| FR2712808B1 (fr) | 1993-11-25 | 1996-02-16 | Esteve Labor Dr | Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique . |
| IL112759A0 (en) | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
| US5776718A (en) | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| AU713492B2 (en) | 1995-03-24 | 1999-12-02 | Axys Pharmaceuticals, Inc. | Reversible protease inhibitors |
| TW438591B (en) | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
| FR2742052B1 (fr) | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
| PT912601E (pt) | 1996-04-22 | 2004-04-30 | Massachusetts Inst Technology | Supressao da resposta imune via inibicao da catepsina s |
| AU7553198A (en) | 1997-06-12 | 1998-12-30 | Sumitomo Pharmaceuticals Company, Limited | Pyrazole derivatives |
| DE69841871D1 (en) | 1997-11-05 | 2010-10-14 | Novartis Ag | Dipeptide nitrile |
| GB9806287D0 (en) | 1998-03-24 | 1998-05-20 | Synphar Lab Inc | Monobactam enzyme inhibitors |
| WO1999058153A1 (en) | 1998-05-08 | 1999-11-18 | Brigham & Women's Hospital | Methods of diagnosing and modulating autoimmunity |
| AU2560000A (en) | 1999-02-20 | 2000-09-04 | Astrazeneca Ab | Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin |
| EP1159273A1 (en) | 1999-03-02 | 2001-12-05 | Boehringer Ingelheim Pharmaceuticals Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| TW200404789A (en) | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| ATE326454T1 (de) | 1999-07-30 | 2006-06-15 | Boehringer Ingelheim Pharma | Neue bernsteinsäure derivative als cysteine- protease-inhibitoren |
| EP1212302A1 (en) | 1999-09-16 | 2002-06-12 | Axys Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| WO2001040204A1 (fr) | 1999-12-03 | 2001-06-07 | Ono Pharmaceutical Co., Ltd. | Derives de 1.3.4-oxadiazoline et medicaments contenant ces derives utiles comme ingredients actifs |
| MXPA03001422A (es) * | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles substituidos. |
-
2001
- 2001-08-10 MX MXPA03001422A patent/MXPA03001422A/es active IP Right Grant
- 2001-08-10 NZ NZ524191A patent/NZ524191A/en not_active IP Right Cessation
- 2001-08-10 EP EP01965898A patent/EP1309593B1/en not_active Expired - Lifetime
- 2001-08-10 PL PL360696A patent/PL213103B1/pl unknown
- 2001-08-10 RU RU2003107016/04A patent/RU2317988C2/ru not_active Application Discontinuation
- 2001-08-10 US US09/927,324 patent/US6953793B2/en not_active Expired - Lifetime
- 2001-08-10 AT AT01965898T patent/ATE320427T1/de active
- 2001-08-10 DE DE60118004T patent/DE60118004T2/de not_active Expired - Lifetime
- 2001-08-10 KR KR1020037002163A patent/KR100837193B1/ko not_active Expired - Lifetime
- 2001-08-10 HU HU0303108A patent/HU230538B1/hu not_active IP Right Cessation
- 2001-08-10 AU AU8645401A patent/AU8645401A/xx active Pending
- 2001-08-10 BR BRPI0113286A patent/BRPI0113286B8/pt not_active IP Right Cessation
- 2001-08-10 DK DK01965898T patent/DK1309593T3/da active
- 2001-08-10 JP JP2002519455A patent/JP5049447B2/ja not_active Expired - Lifetime
- 2001-08-10 PT PT01965898T patent/PT1309593E/pt unknown
- 2001-08-10 CA CA2419552A patent/CA2419552C/en not_active Expired - Lifetime
- 2001-08-10 AU AU2001286454A patent/AU2001286454B2/en not_active Expired
- 2001-08-10 CZ CZ2003-429A patent/CZ307185B6/cs not_active IP Right Cessation
- 2001-08-10 ES ES01965898T patent/ES2261463T3/es not_active Expired - Lifetime
- 2001-08-10 WO PCT/US2001/025290 patent/WO2002014315A2/en active IP Right Grant
-
2003
- 2003-07-10 HK HK03104996A patent/HK1055422A1/xx not_active IP Right Cessation
-
2005
- 2005-06-30 US US11/174,077 patent/US20050245576A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303108A2 (hu) | Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302475A2 (hu) | Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával | |
| HUP0001507A2 (hu) | Pirrolo [2,3-d] pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP9701596A2 (hu) | 2,4-Diamino-1,3,5-triazin-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203425A2 (en) | Quinazoline derivatives, process for their preparation and their use | |
| HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0001498A2 (hu) | Farnezil-transzferáz-gátló 1,8-anellált imidazolil-kinolinon-származékok, intermedierjeik, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0103511A2 (hu) | Oxazolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
| HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
| HUP0002104A2 (hu) | Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0102422A2 (hu) | Rákellenes hatású izotiazolszármazékok, ilyen vegyületeket tartalmazó gyógyszerkészítmények és az előállítási eljárások | |
| HUP9802323A2 (hu) | Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
| HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
| HUP0101281A2 (hu) | Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0402336A2 (hu) | Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0302167A2 (hu) | Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| YU59602A (sh) | Aril fuzionisana azapoliciklična jedinjenja | |
| HUP0300641A2 (hu) | Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| NO930059L (no) | O-glykosylert ifn-alfa | |
| HUP0204283A2 (hu) | (Kinolil-propil)-piperidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE68914292D1 (de) | Zusammensetzung zur Behandlung von ischämischen Störungen in Organen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |